Search

everythinglearnresearchcommunity

for

Search:↓

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Men with baldness on the top of their head might have a small increased risk of prostate cancer.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

Vitamin D may help regulate cholesterol and influence prostate cancer development.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

Finasteride helps with prostate symptoms but may cause sexual side effects.

Finasteride reduces prostate size and PSA levels in young patients.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

Androgen levels can increase at any age, affecting symptoms like acne, hair loss, and prostate size.

Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.

Hair loss is a common side effect of hormone treatments for cancer.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

New sulfur-containing steroid analogs show promise for more targeted medical treatments.

The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.

Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.

Higher PSA levels can indicate prostate cancer, but there's overlap with non-cancerous conditions.

Nephrolepis biserrata may improve fertility and reduce prostate issues in males.

Finasteride reduces certain hormone levels to treat prostate issues.

People with hair loss may have worse urinary symptoms due to an enlarged prostate.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.